Skip to main content

Table 3 Secondary endpoints power analysis

From: Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial

Secondary Endpoint

Assumed Rate in CT-Guided SBRT Arm

Absolute Difference at 80% Power (n = 150 per arm)

Acute grade ≥ 2 GI toxicity

16.0%

8.3%

Late grade ≥ 2 GU toxicity

13.3%

12.8%

Late grade ≥ 2 GI toxicity

2.0%

7.5%